Altimmune to Host Key Opinion Leader Call with Dr. Stephen Harrison on Pemvidutide Phase 1 Clinical Trial Results on September 30, 2021 GAITHERSBURG, Md., Sept. 29, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will host a Key Opinion Leader (KOL) call on...

Altimmune Announces Positive Results From 12-week Phase 1 Clinical Trial of ALT-801 (Pemvidutide) in Overweight and Obese Volunteers Mean weight loss of 10.3% achieved in subjects receiving 1.8 mg dosePemvidutide was well-tolerated without the need for dose titration No discontinuations due to treatment-emergent adverse eventsNASH...

Altimmune to Announce 12-Week Data From ALT-801 Phase 1 Trial on September 28, 2021 GAITHERSBURG, Md., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report the results from its 12-week...

Altimmune to Present at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15, 2021 GAITHERSBURG, Md., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the management team will present...